Publications by authors named "Charalampos Gousis"
This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on humoral and cellular immunity in patients with solid cancers, patients with hematologic malignancies, and persons without cancer. For all cohorts, virus-neutralizing immunity was significantly depleted over a period of up to 9 months following the second vaccine dose, the one striking exception being IL2 production by SARS-CoV-2 antigen-specific T cells. Immunity was restored by the third vaccine dose, except in a substantial number of patients with hematologic malignancy, for whom both cancer type and treatment schedule were associated with nonresponse.
View Article and Find Full Text PDFBackground: During the COVID pandemic, there was a paucity of data to support clinical decision-making for anticancer treatments. We evaluated the safety of radical treatments which were delivered whilst mitigating the risks of concurrent COVID-19 infection.
Methods: Using descriptive statistics, we report on the characteristics and short-term clinical outcomes of patients undergoing radical cancer treatment during the first COVID-19 wave compared to a similar pre-pandemic period.
Article Synopsis
- The study evaluated cancer patients receiving systemic anti-cancer treatment (SACT) at Guy's Cancer Centre during the COVID-19 pandemic to guide future clinical practices.
- A total of 2120 patients received SACT in 2020, a 13% decrease compared to 2449 in 2019, with notable changes in treatment types and stages, including an increase in stage IV cases.
- Despite the pandemic's challenges, the findings indicate that SACT continued effectively with a low SARS-CoV2 infection rate of 2%, suggesting minimal impact on patient mortality for those with solid tumors.